Press releasesKeep up with the latest news from Ikena Oncology.January 28, 2020 Ikena Oncology Announces Dosing of First Patient in Phase 1 Study Evaluating IK-175 in Patients with Advanced Solid TumorsDecember 3, 2019 Kyn Therapeutics Rebrands as Ikena Oncology, Reflecting Next Phase of GrowthMay 7, 2019 Kyn Therapeutics Strengthens Leadership Team with Key AppointmentsFebruary 4, 2019 Kyn Therapeutics Appoints Douglas Carlson as Chief Financial OfficerJanuary 18, 2019 Kyn Therapeutics Enters into Global Strategic Collaboration with Celgene to Develop Immuno-oncology TherapiesDecember 19, 2018 Kyn Therapeutics Announces Initiation of Phase 1b/2 Clinical Studies of ARY-007 in Collaboration with MerckMarch 21, 2018 Kyn Therapeutics Appoints Chairman and Scientific Advisory Board MemberDecember 14, 2017 Kyn Therapeutics Announces $49 Million Series A Capital Available to Develop Cancer Therapy Candidates with Novel Approaches to Major Immunometabolism PathwaysAccess our media kit page to view and download assorted corporate assets.View Media Kit
